Supplementary Table 2 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer In Vivo

Chong Li,Zhao Yang,Ying Du,Haidong Tang,Jun Chen,Deqing Hu,Zusen Fan

DOI: https://doi.org/10.1158/1078-0432.22461191.v1

2023-01-01

Abstract:Relationship between expression levels of the BCMab1 epitope and clinicopathological features of human bladder cancers.

What problem does this paper attempt to address?

Supplementary Table 2 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer In Vivo

Chong Li,Zhao Yang,Ying Du,Haidong Tang,Jun Chen,Deqing Hu,Zusen Fan

DOI: https://doi.org/10.1158/1078-0432.22461191

2023-01-01

Abstract:Relationship between expression levels of the BCMab1 epitope and clinicopathological features of human bladder cancers.
Supplementary Table 1 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer In Vivo

Chong Li,Zhao Yang,Ying Du,Haidong Tang,Jun Chen,Deqing Hu,Zusen Fan

DOI: https://doi.org/10.1158/1078-0432.22461194

2023-01-01

Abstract:FACS and immunohistochemistry analysis of BCMab1 immunoreactivity to human cell lines and normal human tissues.
Supplementary Table 4 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer In Vivo

Chong Li,Zhao Yang,Ying Du,Haidong Tang,Jun Chen,Deqing Hu,Zusen Fan

DOI: https://doi.org/10.1158/1078-0432.22461185.v1

2023-01-01

Abstract:Complete information of the detected glycans by glycochip assay.
Supplementary Table 3 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer In Vivo

Chong Li,Zhao Yang,Ying Du,Haidong Tang,Jun Chen,Deqing Hu,Zusen Fan

DOI: https://doi.org/10.1158/1078-0432.22461188

2023-01-01

Abstract:Complete information of the detected peptides for the six bands of I and II by mass spectrometry.
Supplementary Figure 2 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer In Vivo

Chong Li,Zhao Yang,Ying Du,Haidong Tang,Jun Chen,Deqing Hu,Zusen Fan

DOI: https://doi.org/10.1158/1078-0432.22461212.v1

2023-01-01

Abstract:BCMab1 recognizes the aberrantly glycosylated Integrin α3 on bladder cancer and GALNT1 silencing impairs BCMab1 staining.
Supplementary Figure 1 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer In Vivo

Chong Li,Zhao Yang,Ying Du,Haidong Tang,Jun Chen,Deqing Hu,Zusen Fan

DOI: https://doi.org/10.1158/1078-0432.22461215.v1

2023-01-01

Abstract:BCMab1 antibody suppressed cancerous growth in mice bearing primary human bladder cancer cells.
Supplementary Table 6 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer In Vivo

Chong Li,Zhao Yang,Ying Du,Haidong Tang,Jun Chen,Deqing Hu,Zusen Fan

DOI: https://doi.org/10.1158/1078-0432.22461179.v1

2023-01-01

Abstract:Fucosyltransferases (FUT) are no significant changes in the bladder cancer compared to the normal bladder tissues.
Supplementary Table 5 from BCMab1, A Monoclonal Antibody Against Aberrantly Glycosylated Integrin Α3β1, Has Potent Antitumor Activity of Bladder Cancer in Vivo

Chong Li,Zhao Yang,Ying Du,Haidong Tang,Jun Chen,Deqing Hu,Zusen Fan

DOI: https://doi.org/10.1158/1078-0432.22461182.v1

2023-01-01

Abstract:GALNT1 is highly expressed in the bladder cancer among all the N-acetylgalactosaminyltransferases.
Supplementary Figure 6 from BCMab1, A Monoclonal Antibody Against Aberrantly Glycosylated Integrin Α3β1, Has Potent Antitumor Activity of Bladder Cancer in Vivo

Chong Li,Yao Zhao,Youwei Du,Haidong Tang,Jun Chen,Deqing Hu,Zusen Fan

DOI: https://doi.org/10.1158/1078-0432.22461200

2023-01-01

Abstract:BCMab1 antibody treatment promotes tumor-inside NK cell cytolysis.
Supplementary Figure 3 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer In Vivo

Chong Li,Zhao Yang,Ying Du,Haidong Tang,Jun Chen,Deqing Hu,Zusen Fan

DOI: https://doi.org/10.1158/1078-0432.22461209.v1

2023-01-01

Abstract:Integrin α3 or GALNT1 knockdown inhibits bladder cancer growth.
Supplementary Figure 5 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer In Vivo

Chong Li,Zhao Yang,Ying Du,Haidong Tang,Jun Chen,Deqing Hu,Zusen Fan

DOI: https://doi.org/10.1158/1078-0432.22461203

2023-01-01

Abstract:Deletion of Integrin α3 in T24 or HCV29 cells by TALEN.
Supplementary Figure 4 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer In Vivo

Chong Li,Zhao Yang,Ying Du,Haidong Tang,Jun Chen,Deqing Hu,Zusen Fan

DOI: https://doi.org/10.1158/1078-0432.22461206.v1

2023-01-01

Abstract:GALNT1 knockdown in LNCaP cells has no effect on attachment, transmigration, colony formation, and wound healing.
BCMab1, a Monoclonal Antibody Against Aberrantly Glycosylated Integrin Α3β1, Has Potent Antitumor Activity of Bladder Cancer in Vivo.

Chong Li,Zhao Yang,Ying Du,Haidong Tang,Jun Chen,Deqing Hu,Zusen Fan

DOI: https://doi.org/10.1158/1078-0432.ccr-13-3397

IF: 13.801

2014-01-01

Clinical Cancer Research

Abstract:Abstract Purpose: To identify a novel biomarker for bladder cancer targeting therapy. Experimental Design: The human bladder cancer cell line T24 cells were used as immunogen to generate mouse monoclonal antibodies. We screened and identified a specific antibody BCMab1 against bladder cancer. We examined BCMab1 antigen expression in the patients with bladder cancer through immunohistochemical staining and investigated the BCMab1 antigen association with clinical severity. We detected the antitumor activity of BCMab1 antibody and investigated its therapeutic efficacy by subcutaneous and orthotopic bladder cancer models. Results: We developed a new monoclonal antibody BCMab1 against bladder cancer that specifically recognized the aberrantly glycosylated Integrin α3β1 epitope on bladder cancer cells. Expression of the BCMab1 antigen was consistent with clinical severity and prognosis of bladder cancer. The glycosyltransferase GALNT1 could contribute to aberrant glycosylation of Integrin α3. The aberrant glycosylation of integrin α3–activated integrin signaling to initiate FAK activation. BCMab1 could block Integrin engagement to inhibit its signaling leading to cell-cycle arrest. In addition, BCMab1 enhanced FcγR-dependent antitumor activity in vivo. Conclusions: BCMab1 antigen is a new biomarker for bladder cancer. BCMab1 antibody exhibited potent antitumor activity against bladder cancer in vivo. Clin Cancer Res; 20(15); 4001–13. ©2014 AACR.
Supplementary Materials and Legends from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer In Vivo

Chong Li,Zhao Yang,Ying Du,Haidong Tang,Jun Chen,Deqing Hu,Zusen Fan

DOI: https://doi.org/10.1158/1078-0432.22461197

2023-01-01

Abstract:Supplementary Materials and Legends
BCMab1-Ra, a Novel Immunotoxin That BCMab1 Antibody Coupled to Ricin A Chain, Can Eliminate Bladder Tumor.

Chong Li,Ruping Yan,Zhao Yang,Haifeng Wang,Ruiyun Zhang,Haige Chen,Jiansong Wang

DOI: https://doi.org/10.18632/oncotarget.13504

2016-01-01

Oncotarget

Abstract:Bladder cancer is one of the most common malignancies. However, there is no ideal therapy to cure bladder cancer so far, especially invasive carcinoma. Here, we developed a new antibody-based drug BCMab1-Ra, which was generated by conjugation of BCMab1 (a new monoclonal antibody that specifically recognized the aberrantly glycosylated Integrin a3b1 in bladder cancer) with the ricin A chain (Ra). A patient with multiple bladder cancer received intravescical administration of BCMab1-Ra treatment as a volunteer. After 30 weeks of treatment, no tumor was observed by cystoscope examination. We did not observe any local or systemic side effects. Human anti-mouse antibody (HAMA) was not detectable in the circulation. Results follow-up showed no tumor had been found in every half year review in 3 years.

Supplementary Table 2 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer <i>In Vivo</i>

Supplementary Table 2 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer <i>In Vivo</i>

Supplementary Table 1 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer <i>In Vivo</i>

Supplementary Table 4 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer <i>In Vivo</i>

Supplementary Table 3 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer <i>In Vivo</i>

Supplementary Figure 2 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer <i>In Vivo</i>

Supplementary Figure 1 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer <i>In Vivo</i>

Supplementary Table 6 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer <i>In Vivo</i>

Supplementary Table 5 from BCMab1, A Monoclonal Antibody Against Aberrantly Glycosylated Integrin Α3β1, Has Potent Antitumor Activity of Bladder Cancer in Vivo

Supplementary Figure 6 from BCMab1, A Monoclonal Antibody Against Aberrantly Glycosylated Integrin Α3β1, Has Potent Antitumor Activity of Bladder Cancer <i>in Vivo</i>

Supplementary Figure 3 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer <i>In Vivo</i>

Supplementary Figure 5 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer <i>In Vivo</i>

Supplementary Figure 4 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer <i>In Vivo</i>

BCMab1, a Monoclonal Antibody Against Aberrantly Glycosylated Integrin Α3β1, Has Potent Antitumor Activity of Bladder Cancer in Vivo.

Supplementary Materials and Legends from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer <i>In Vivo</i>

BCMab1-Ra, a Novel Immunotoxin That BCMab1 Antibody Coupled to Ricin A Chain, Can Eliminate Bladder Tumor.

Supplementary Table 2 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer &lt;i&gt;In Vivo&lt;/i&gt;

Supplementary Table 2 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer &lt;i&gt;In Vivo&lt;/i&gt;

Supplementary Table 1 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer <i>In Vivo</i>

Supplementary Table 4 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer &lt;i&gt;In Vivo&lt;/i&gt;

Supplementary Table 3 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer &lt;i&gt;In Vivo&lt;/i&gt;

Supplementary Figure 2 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer <i>In Vivo</i>

Supplementary Figure 1 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer &lt;i&gt;In Vivo&lt;/i&gt;

Supplementary Table 6 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer &lt;i&gt;In Vivo&lt;/i&gt;

Supplementary Table 5 from BCMab1, A Monoclonal Antibody Against Aberrantly Glycosylated Integrin Α3β1, Has Potent Antitumor Activity of Bladder Cancer in Vivo

Supplementary Figure 6 from BCMab1, A Monoclonal Antibody Against Aberrantly Glycosylated Integrin Α3β1, Has Potent Antitumor Activity of Bladder Cancer &lt;i&gt;in Vivo&lt;/i&gt;

Supplementary Figure 3 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer &lt;i&gt;In Vivo&lt;/i&gt;

Supplementary Figure 5 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer &lt;i&gt;In Vivo&lt;/i&gt;

Supplementary Figure 4 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer &lt;i&gt;In Vivo&lt;/i&gt;

BCMab1, a Monoclonal Antibody Against Aberrantly Glycosylated Integrin Α3β1, Has Potent Antitumor Activity of Bladder Cancer in Vivo.

Supplementary Materials and Legends from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer &lt;i&gt;In Vivo&lt;/i&gt;

BCMab1-Ra, a Novel Immunotoxin That BCMab1 Antibody Coupled to Ricin A Chain, Can Eliminate Bladder Tumor.

Supplementary Table 2 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer <i>In Vivo</i>

Supplementary Table 2 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer <i>In Vivo</i>

Supplementary Table 4 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer <i>In Vivo</i>

Supplementary Table 3 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer <i>In Vivo</i>

Supplementary Figure 1 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer <i>In Vivo</i>

Supplementary Table 6 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer <i>In Vivo</i>

Supplementary Figure 6 from BCMab1, A Monoclonal Antibody Against Aberrantly Glycosylated Integrin Α3β1, Has Potent Antitumor Activity of Bladder Cancer <i>in Vivo</i>

Supplementary Figure 3 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer <i>In Vivo</i>

Supplementary Figure 5 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer <i>In Vivo</i>

Supplementary Figure 4 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer <i>In Vivo</i>

Supplementary Materials and Legends from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer <i>In Vivo</i>